Influence of Human Albumin Supplementation on Kidney Dysfunction After Liver Transplantation

Launched by RENNES UNIVERSITY HOSPITAL · Jul 30, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a treatment called human albumin on kidney function after liver transplantation. Specifically, the researchers want to see if giving patients higher levels of albumin (above 30 grams per liter) for five days can help reduce the chances of acute kidney injury (AKI) within the first week after their liver transplant. They are comparing this approach to a more limited albumin treatment, where levels are kept at 20 grams per liter or lower.

To participate, you must be at least 18 years old and have received a liver transplant from a deceased donor. The trial is open to both men and women who are able to understand the study and give their consent. However, if you have severe liver disease, pre-existing kidney problems, or are involved in another clinical study, you may not be eligible. Participants can expect to receive either the higher or lower dose of albumin and will be monitored closely for kidney function over the course of the study. This research is important because it could help improve kidney health in patients following liver transplantation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male and female subjects equal or above 18 yrs old.
• • Recipients of primary liver allografts from a deceased donor (including after cardiac death) and as a single organ (liver only).
• • Capability of understanding the purpose and risks of the study.
• • Written informed consent
• Exclusion Criteria:
• • Fulminant hepatitis
• • Kidney injury at baseline (Estimated Glomerular Filtration Rate \< 50 ml/min in Modification of diet in renal disease-6) including hepatorenal syndrome
• • Use of an induction agent Basiliximab at liver transplantation
• • Protected person (adults legally protected, under judicial protection, guardianship, or supervision), person deprived of their liberty
• • At the time of randomisation, participation to another interventional study